Related Experiment Video
Updated: Mar 24, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
The Clinical Implications of RSK1-3 in Human Breast Cancer
Huishan Zhao1, Tracey A Martin2, Eleri L Davies3
1Cardiff-China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, U.K. Department of Biochemistry and Molecular Biology, Basic Medicine School, Cancer Institute of Capital Medical University, Beijing, P.R. China Capital Medical University-Cardiff University Joint Centre for Biomedical Research; Beijing International Cooperation Base for Science and Technology on China-UK Cancer Research, Capital Medical University, Beijing, P.R. China Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Beijing, P.R. China.
Background/Aim:
The ribosomal S6 protein kinase (RSK) family is an important effector of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) that could influence tumour metastasis by phosphorylating proteins in both the nuclear and cytoplasmic compartments. Aberrant expression of RSK is evident in certain malignancies but the role played by RSK in breast cancer is still not clear. This study aimed to examine the expression of RSK in human breast cancer specimens and its role to breast cancer metastasis.
Materials And Methods:
The expression of RSK1 to -3 were separately examined in human breast cancer tissues (normal, n=33; cancer, n=112) using quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemistry. Migration and adhesion of breast cancer cells treated with the RSK inhibitor SL0101 were investigated by electric cell impedance sensing (ECIS). The effect on growth and invasion of RSK1-3 was then investigated using in vitro models.
Results:
The clinical data and immunohistochemistry revealed that expression of RSK1 and RSK3 were less in tumour tissues than normal. mRNA expression of RSK2 was negatively correlated with grade, TNM staging, and survival rate. SL0101 inhibited adhesion of the MCF-7 and MDA-231 breast cancer cell lines. SL0101 suppressed MDA-231 invasion and the alternate RSK inhibitor BRD7389 inhibited the invasion of MCF-7 and MDA-231 cells.
Conclusion:
RSK1 and 3 but not RSK2 are down-regulated in breast tumour and are associated with disease progression. RSK may be a key component in the progression and metastasis of breast cancer.
Insights
Ribosomal S6 protein kinase (RSK) family members RSK1 and RSK3 are down-regulated in breast tumors, impacting disease progression. RSK inhibition suppresses breast cancer cell adhesion and invasion, suggesting RSK is crucial for metastasis.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- The ribosomal S6 protein kinase (RSK) family, a key effector of ERK/MAPK signaling, influences tumor metastasis through protein phosphorylation.
- Aberrant RSK expression is observed in malignancies, but its specific role in breast cancer remains unclear.
Purpose of the Study:
- To investigate the expression of RSK1-3 in human breast cancer specimens.
- To determine the role of RSK in breast cancer metastasis and cellular processes like adhesion and invasion.
Main Methods:
- Quantitative real-time PCR (Q-PCR) and immunohistochemistry were used to assess RSK1-3 expression in 112 breast cancer tissues and 33 normal tissues.
- Breast cancer cell lines (MCF-7 and MDA-231) were treated with RSK inhibitors (SL0101, BRD7389) to evaluate effects on migration, adhesion, and invasion using electric cell impedance sensing (ECIS) and in vitro models.
Main Results:
- RSK1 and RSK3 expression were significantly lower in tumor tissues compared to normal tissues.
- RSK2 mRNA expression negatively correlated with tumor grade, TNM stage, and patient survival rate.
- RSK inhibition by SL0101 reduced adhesion in MCF-7 and MDA-231 cells and suppressed MDA-231 invasion. BRD7389 inhibited invasion in both cell lines.
Conclusions:
- RSK1 and RSK3 are downregulated in breast tumors and linked to disease progression.
- RSK signaling plays a critical role in breast cancer progression and metastasis.
- Targeting RSK may offer a therapeutic strategy for breast cancer treatment.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene
Ras is a...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

